STOCK TITAN

MXL Insider Plans to Sell 102,157 Shares via Morgan Stanley ($1.77M)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

MaxLinear, Inc. (MXL) filed a Form 144 notifying a proposed sale of 102,157 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $1,765,108.49. The filing lists approximately 87,080,498 shares outstanding and an approximate sale date of 08/26/2025. The securities to be sold were acquired in three grants: 1,277 shares via an Employee Stock Purchase Plan on 05/17/2021, 47,725 restricted shares on 02/22/2019, and 53,155 performance shares on 02/17/2021. No sales by the seller were reported in the past three months. The signer certifies they have no undisclosed material adverse information about the issuer.

Positive

  • Transparent disclosure of the number of shares and acquisition types (ESPP, restricted, performance) supporting compliance
  • Brokered sale through Morgan Stanley Smith Barney suggests an orderly transaction rather than distressed selling
  • No sales in past three months indicates the filer has not been actively disposing of large holdings recently

Negative

  • None.

Insights

TL;DR: Routine insider sale notice for 102,157 shares valued at $1.77M; appears procedural, not an earnings or operational signal.

This Form 144 reports a proposed sale by a person holding shares acquired from an ESPP, restricted stock, and performance shares. The sale size represents about 0.12% of the reported outstanding shares (102,157 of 87,080,498). The use of a major brokerage and the absence of recent sales suggest a planned, orderly disposition rather than urgent liquidation. There is no disclosure of material nonpublic information; the filer makes the standard certification.

TL;DR: Governance process followed: required disclosure filed and seller attests to no undisclosed material information.

The Form 144 provides the required regulatory notice for selling restricted and performance-based equity. Acquisition dates and grant types are disclosed, which supports transparency around insider liquidity. The filing notes no sales in the prior three months, aligning with controlled selling practices. This is a routine compliance filing rather than a governance red flag.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does MaxLinear's (MXL) Form 144 report?

The filing reports a proposed sale of 102,157 common shares with an aggregate market value of $1,765,108.49 to be sold through Morgan Stanley Smith Barney.

When is the proposed sale date listed on the Form 144 for MXL?

The Form 144 shows an approximate sale date of 08/26/2025.

How were the shares being sold by the MXL filer originally acquired?

They were acquired via an Employee Stock Purchase Plan (1,277 shares on 05/17/2021), restricted stock (47,725 shares on 02/22/2019), and performance shares (53,155 shares on 02/17/2021).

Does the Form 144 indicate recent sales by the filer in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

What certification does the seller provide in the Form 144?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.